Category | Column name | Description | Example |
---|---|---|---|
Mutation prioritization output | Gene name | HUGO name of the gene | ARAF |
Chromosome number | Chromosome number of this mutation | 1 | |
Coordinate | Genomic coordinate of the mutation | 1234560 | |
Reference allele | Reference allele of this mutation | C | |
Alternative allele | Alternative allele of this mutation | G | |
Mutation category | Whether this mutation is a point coding mutation, point non-coding mutation, or structural variation | Point coding mutation | |
Mutation context | Genomic context of the mutation | c.641C > G | |
Protein context | Protein context of the mutation | p.S214C | |
Score category | If the mutation is a point coding mutation, then the category is the radial SVM score; if a point non-coding mutation, then Funseq2 score; if structural variation, then normalized CNV signal score | Radial SVM | |
Driver mutation score | Value of the corresponding score | 0.932 | |
Gene prioritization output | Gene name | HUGO name of the gene | ARAF |
Gene category | Whether this gene belongs to the Cancer Gene Census, KEGG Cancer Pathway, or other categories | KEGG cancer pathway | |
Maximum radial SVM score | Maximum radial SVM score of all point coding mutations in the gene | 0.932 | |
Maximum FunSeq2 Score | Maximum FunSeq2 score of all point non-coding mutations in the gene | 0.000 | |
Maximum normalized CNV Signal score | Maximum normalized CNV signal score of all structural variations in the gene | 0.000 | |
Phenolyzer score | Phenolyzer score of the gene | 0.306 | |
iCAGES gene score | iCAGES gene score of the gene | 0.484 | |
Drug prioritization output | Drug name | Name of the drug | SORAFENIB |
Final target gene | Mutated gene in the patient finally targeted by the drug | ARAF | |
Direct target gene | Mutated gene in the patient directly targeted by the drug | ARAF | |
iCAGES gene score | iCAGES gene score of the target gene | 0.484 | |
BioSystems normalized Relatedness probability | BioSystems normalized relatedness probability between the direct target of the drug and the target gene | 1.000 | |
PubChem normalized drug active probability | PubChem normalized drug active probability of this drug | 1.000 | |
iCAGES drug score | iCAGES drug score of the drug | 0.484 | |
Tier | Which tier this drug belongs to, whether it is FDA approved (tier 1), undergoing clinical trials (tier 2) or otherwise (tier 3). | 1 | |
Brand name | Commercial brand name of this drug | NEXAVAR | |
FDA approved subtype | What cancer subtypes approved by FDA can this drug be applied to | Hepatocellular carcinoma, renal cancer, thyroid cancer | |
Clinical trial name | The name of the active clinical trials on this drug | Sorafenib phase II study for Japanese anaplastic or medullary thyroid carcinoma patients | |
Clinical trial organization | The organization for this clinical trial | BAYER | |
Clinical trial phase | Phase of this clinical trial | 2 | |
Clinical trial URL | URL of this clinical trial |